Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema
Purpose. In this study, we describe a new surgical technique for the treatment of refractory DME. The technique consists of vitrectomy with ILM peeling with a subretinal injection of ranibizumab. Methods. This is a prospective interventional noncomparative study including patients with refractory DM...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2019/6274209 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563847125270528 |
|---|---|
| author | Samir M. El-Baha Ahmed M. Abdel Hadi Mahmoud A. Abouhussein |
| author_facet | Samir M. El-Baha Ahmed M. Abdel Hadi Mahmoud A. Abouhussein |
| author_sort | Samir M. El-Baha |
| collection | DOAJ |
| description | Purpose. In this study, we describe a new surgical technique for the treatment of refractory DME. The technique consists of vitrectomy with ILM peeling with a subretinal injection of ranibizumab. Methods. This is a prospective interventional noncomparative study including patients with refractory DME. Included patients were subjected to the new surgical technique of pars plana vitrectomy with subretinal injection of ranibizumab. Results. The study included 19 eyes with refractory macular edema, in which this novel technique was attempted. There were 10 males and 9 females. The age of the patients ranged from 17 to 67 years with a mean of 55.58 ± 13.242 years. The duration of diabetes before enrollment in the study ranged from 7 to 25 years with a mean of 16.3 years. Preoperatively, the mean CMT of the eyes ranged from 352 to 883 microns with mean ± SD of 498.58 ± 152.16 microns. Postoperatively, this improved significantly to 373.5 ± 100.3, 355.9 ± 89.8, and 365.74 ± 120.12 microns at 1, 3, and 6 months, respectively (p≤0.001 for all). Conclusion. This novel surgical procedure of vitrectomy with ILM peeling with a subretinal injection of ranibizumab is effective in cases of refractory DME. The study has been registered in Contact ClinicalTrials.gov PRS Identifier: NCT03975088. |
| format | Article |
| id | doaj-art-6e04298f2d5246d5a1e315910b5499c6 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-6e04298f2d5246d5a1e315910b5499c62025-02-03T01:12:27ZengWileyJournal of Ophthalmology2090-004X2090-00582019-01-01201910.1155/2019/62742096274209Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular EdemaSamir M. El-Baha0Ahmed M. Abdel Hadi1Mahmoud A. Abouhussein2Ophthalmology Department, Alexandria University, Alexandria, EgyptOphthalmology Department, Alexandria University, Alexandria, EgyptOphthalmology Department, Alexandria University, Alexandria, EgyptPurpose. In this study, we describe a new surgical technique for the treatment of refractory DME. The technique consists of vitrectomy with ILM peeling with a subretinal injection of ranibizumab. Methods. This is a prospective interventional noncomparative study including patients with refractory DME. Included patients were subjected to the new surgical technique of pars plana vitrectomy with subretinal injection of ranibizumab. Results. The study included 19 eyes with refractory macular edema, in which this novel technique was attempted. There were 10 males and 9 females. The age of the patients ranged from 17 to 67 years with a mean of 55.58 ± 13.242 years. The duration of diabetes before enrollment in the study ranged from 7 to 25 years with a mean of 16.3 years. Preoperatively, the mean CMT of the eyes ranged from 352 to 883 microns with mean ± SD of 498.58 ± 152.16 microns. Postoperatively, this improved significantly to 373.5 ± 100.3, 355.9 ± 89.8, and 365.74 ± 120.12 microns at 1, 3, and 6 months, respectively (p≤0.001 for all). Conclusion. This novel surgical procedure of vitrectomy with ILM peeling with a subretinal injection of ranibizumab is effective in cases of refractory DME. The study has been registered in Contact ClinicalTrials.gov PRS Identifier: NCT03975088.http://dx.doi.org/10.1155/2019/6274209 |
| spellingShingle | Samir M. El-Baha Ahmed M. Abdel Hadi Mahmoud A. Abouhussein Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema Journal of Ophthalmology |
| title | Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema |
| title_full | Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema |
| title_fullStr | Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema |
| title_full_unstemmed | Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema |
| title_short | Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema |
| title_sort | submacular injection of ranibizumab as a new surgical treatment for refractory diabetic macular edema |
| url | http://dx.doi.org/10.1155/2019/6274209 |
| work_keys_str_mv | AT samirmelbaha submacularinjectionofranibizumabasanewsurgicaltreatmentforrefractorydiabeticmacularedema AT ahmedmabdelhadi submacularinjectionofranibizumabasanewsurgicaltreatmentforrefractorydiabeticmacularedema AT mahmoudaabouhussein submacularinjectionofranibizumabasanewsurgicaltreatmentforrefractorydiabeticmacularedema |